Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
322 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
Condition: Anemia, Sickle Cell
Interventions: Drug: Rivipansel;   Other: Placebo
22 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
23 Recruiting Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Conditions: Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
24 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
25 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
26 Enrolling by invitation Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS
Condition: Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: UX007
27 Recruiting Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Panobinostat;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Intrathecal Triples;   Drug: Leucovorin
28 Recruiting Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine
29 Completed Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine
30 Active, not recruiting National Marrow Donor Program Long-Term Donor Follow-Up
Condition: Hematologic Neoplasms
Intervention:
31 Active, not recruiting Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: Drug: UX007 (triheptanoin);   Drug: Placebo Oil
32 Recruiting Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Conditions: Solid Tumors;   CNS Tumors;   Neuroblastoma
Intervention: Drug: Entrectinib
33 Recruiting Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
Condition: Respiratory Distress Syndrome
Interventions: Drug: Lucinactant delivered via investigational delivery device;   Drug: nCPAP
34 Recruiting EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients
Condition: Cystic Fibrosis
Interventions: Drug: CTX-4430;   Drug: Placebo
35 Active, not recruiting A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
Condition: Growth Hormone Deficiency
Intervention: Drug: Somatropin
36 Active, not recruiting Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention:
37 Completed Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: Saline;   Drug: MST-188
38 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
39 Completed Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Intervention: Drug: flecainide
40 Terminated Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.